Prescription Diet Research Articles

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC: 325620)Colgate‐Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC: 325620)Colgate‐Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

Controlled clinical trial of two weight reducing diets in a NHS hospital dietetic outpatient clinic ‐ a pilot study

Outpatient dietary weight reduction for obesity is unsatisfactory. The objective of this study was to compare the efficacy of an energy prescription diet with usual care (a healthy eating diet) in adult overweight patients referred to a NHS hospital dietetic outpatient clinic, in terms of weight change over 12 weeks. Controlled clinical trial (systematic allocation). Of the 53 patients who attended their first appointment, 27 completed the trial. Mean weight loss (kg) after 12 weeks was 4.2 (sd 3.8) on the energy prescription diet (n = 16) and 6.0 (sd 2.8) on the healthy eating diet (n = 11). Patients on a weight reducing diet based on energy prescription or healthy eating lost, on average, clinically significant amounts of body weight by 12 weeks. Mean weight loss was greater by about 50% in the healthy eating group and supports the development of a larger trial to estimate true effect.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC: 325620)Colgate‐Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC: 325620)Colgate‐Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

The PPET Study: People and Pets Exercising Together

Obesity is a significant public health problem that is affecting people and their pets. The human-companion animal bond and the role of pets in providing social support provides a rationale framework for studying the effectiveness of a combined people and pets (PP) exercising together (PPET) weight loss program. Thirty-six pairs of overweight or obese people with an obese pet (PP) and 56 overweight or obese people only (PO) participated in a 1-year prospective controlled weight loss study. In a group format, people received dietary and physical activity counseling, and dogs were fed a calorie-controlled prescription diet. Physical activity was recorded using the physical activity recall questionnaire. Completion rates at 1 year were 61% for the PP group and 58% for the PO group. Mean weight losses at 12 months using last observation carried forward were 4.7% (PP) and 5.2% (PO). Mean weight loss among the dogs was 15%. Time spent in physical activity increased in both groups to 3.9 (PP) and 3.5 (PO) h/wk. Two-thirds of total physical activity in the PP group was spent with the dogs. The PPET study is the first program to demonstrate the effectiveness of a combined PP weight loss program. This fresh approach to the dual obesity epidemic builds on the human-companion animal bond. Consideration of social support for weight loss of family members, friends, and coworkers should be extended to include pets.

Disease Management of the Metabolic Syndrome in a Community: Study Design and Process Analysis on Baseline Data

A comprehensive lifestyle approach is suggested as first-line treatment for the individual features of the metabolic syndrome, but the results in community medicine are usually discouraging. No study has tested the feasibility of an integrated approach between general practitioners (GPs) and specialist centers. We report the process analysis on baseline data of a randomized study based on the integration between GPs, selecting patients on the basis of a pre-defined grid and specific targets, and a specialist center, providing informative material and arranging courses of counseling and cognitive-behavioral therapy, using a shared database. After initial visits by GPs for clinical assessment and motivation to treatment, patients were randomly assigned to: (a) prescriptive diet, managed by GPs; (b) counseling (four group lessons); (c) cognitive-behavioral treatment (12 group lessons), both managed by specialist center. Data of the first 503 subjects were compared with those of 139 cases self-referring to the specialist center for the treatment of obesity. Subjects enrolled by GPs were more frequently males, had lower obesity grades, and a higher number of features of metabolic syndrome, compared with the control group. Only 10% of subjects randomized to counseling and 27% randomized to behavior declined participation in the intensive treatments; attendance at sessions averaged 90%. GPs were satisfied with their participation and reported that treatments met patients' needs. An integrated approach to lifestyle changes between GPs and a specialist center is feasible in the metabolic syndrome and may be cost-effective, considering the high burden of disease.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC: 325620)Colgate‐Palmolive is a global consumer products company. Co.'s Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, laundry and dishwashing detergents, fabric conditioners, cleansers and cleaners, bleaches and other similar items. Co.'s Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Principal global and regional trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

Colgate-Palmolive Co.

Mergent's Dividend AchieversVolume 3, Issue 2 p. 65-65 U.S. Company Reports Colgate-Palmolive Co.† First published: 20 April 2006 https://doi.org/10.1002/div.3873 † Contact: : Reuben Mark — Chmn., C.E.O. Address: : 300 Park Avenue, New York, NY 10022-7499 Web Site: : www.colgate.com AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Chemicals (MIC: 11.1 SIC: 2844 NAIC: 325620) Colgate-Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet. Volume3, Issue2Spring 2006Pages 65-65 RelatedInformation

Colgate-Palmolive Co.

Mergent's Dividend AchieversVolume 3, Issue 3 p. 65-65 U.S. Company Reports Colgate-Palmolive Co.† First published: 30 June 2006 https://doi.org/10.1002/div.4291 † Contact: : Reuben Mark — Chmn., C.E.O. Address: : 300 Park Avenue, New York, NY 10022-7499 Web Site: : www.colgate.com AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Chemicals (MIC: 11.1 SIC: 2844 NAIC: 325620) Colgate-Palmolive manufactures and markets a variety of products in two business segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, detergents, fabric conditioners, cleansers and cleaners and bleaches. Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Axion, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet. Volume3, Issue3Summer 2006Pages 65-65 RelatedInformation

Therapieoptionen für die nicht-alkoholinduzierte Fettleber und Fettleberhepatitis

Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as one of the most common causes of chronic liver damage in the western world. It is strongly associated with insulin resistance, obesity and other features of the metabolic syndrome. The entity NAFLD embraces a clinical spectrum from benign steatosis over steatohepatitis to hepatic cirrhosis with its complications liver failure and hepatocellular carcinoma. Treatment is currently based on prescriptive diet and physical exercise. A well-defined pharmacotherapy of NAFLD still remains to be established due to the lack of randomized, controlled trials. Yet, for several drugs such as Metformin and Thiazolidinediones, smaller trials report promising results.

Assessing Nutritional Riskof Long-Term Care Residents

The validity was determined for Minimum Data Set (MDS) 2.0 oral/nutrition status (Section K) items, used to identify long-term care residents at nutritional risk. A registered dietitian assessed 128 long-term care residents using standardized procedures, and used clinical judgment to provide a nutritional risk rating. Registered nursing staff completed the MDS assessments. Bivariate tests of association were used to assess the relationship between the dietitian rating and each Section K item. The sensitivity (Se) and specificity (Sp) of specific and combinations of variables were also determined. The MDS variables of dietary prescription (diet rx), supplement use, and swallowing problems were significantly associated with nutritional risk rating. Body mass index (BMI), calculated from MDS data, also was significantly associated with nutritional risk rating. The MDS trigger system, however, had poor Se and Sp. The best combination of variables included the presence of one or more of diet rx, supplement use, swallowing problem, or BMI <24 kg/m2 (Se=0.81, Sp=0.50). Although Section K items are associated with nutritional risk, Se and Sp analyses suggest that these items and this section require further refinement and validation before use as part of a referral mechanism.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 844 NAIC: 25620)Colgate‐Palmolive is a global consumer products company. Co.'s Oral, Personal and Home Care products include toothpaste, oral rinses and toothbrushes, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, shave products, laundry and dishwashing detergents, fabric conditioners, cleansers and cleaners, bleaches and other similar items. Co.'s Pet Nutrition products include pet food products manufactured and marketed by Hill's Pet Nutrition. Principal global and regional trademarks include Colgate, Palmolive, Kolynos, Sorriso, Elmex, Mennen, Protex, Softsoap, Irish Spring, Ajax, Soupline, Suavitel, Hill's Science Diet and Hill's Prescription Diet.

A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease

Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated. We aimed to compare the usefulness of metformin versus prescriptive diet or vitamin E. In an open label, randomized trial, nondiabetic NAFLD patients were given metformin (2 g/day; n = 55) for 12 months. The control cases were given either vitamin E (800 IU/day; n = 28) or were treated by a prescriptive, weight-reducing diet (n = 27). Outcome measures were liver enzymes, insulin resistance (homeostasis model assessment), parameters of the metabolic syndrome, and histology. Aminotransferase levels improved in all groups, in association with weight loss. The effects in the metformin arm were larger (p < 0.0001), and alanine aminotransferase normalized in 56% of cases (odds ratio (OR) versus. controls, 3.11; 95% confidence interval (CI), 1.56-6.20; p= 0.0013). In multivariate analysis, metformin treatment was associated with higher rates of aminotransferase normalization, after correction for age, gender, basal aminotransferases, and change in body mass index (OR, 5.98; 95% CI, 2.05-17.45). Differences were maintained when the two control groups were separately analyzed. The distribution of positive criteria for the metabolic syndrome was reduced only in the metformin arm (p= 0.001, signed rank test). A control biopsy in 17 metformin-treated cases (14 nonresponders) showed a significant decrease in liver fat (p= 0.0004), necroinflammation, and fibrosis (p= 0.012 for both). No side effects were observed during metformin treatment. Metformin treatment is better than a prescriptive diet or vitamin E in the therapy of NAFLD patients receiving nutritional counseling. Limited histological data support an association between improved aminotransferases and biopsy findings, which require confirmation in a double-blind trial with appropriate statistical power based on liver histology.

Insulin Resistance from a Low Carbohydrate, High Fat Diet Perspective

Metabolic Syndrome and Related DisordersVol. 3, No. 1 Insulin Resistance from a Low Carbohydrate, High Fat Diet PerspectiveEric C. Westman, William S. YancyJr., Mark D. Haub, and Jeff S. VolekEric C. WestmanSearch for more papers by this author, William S. YancyJr.Search for more papers by this author, Mark D. HaubSearch for more papers by this author, and Jeff S. VolekSearch for more papers by this authorPublished Online:5 Jul 2005https://doi.org/10.1089/met.2005.3.14AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited bySchmerzen als Ausläufer von Stoffwechselbelastungen15 February 2013 | Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine, Vol. 25, No. 1Diabetes PathophysiologyComparison of three commercially available prescription diet regimens on short-term post-prandial serum glucose and insulin concentrations in healthy cats26 March 2009 | Veterinary Research Communications, Vol. 33, No. 7Carbohydrate-restricted versus low-glycemic-index diets for the treatment of insulin resistance and metabolic syndromeNutrition Reviews, Vol. 67, No. 3Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal8 April 2008 | Nutrition & Metabolism, Vol. 5, No. 1Nonequilibrium thermodynamics and energy efficiency in weight loss diets30 July 2007 | Theoretical Biology and Medical Modelling, Vol. 4, No. 1Low-carbohydrate nutrition and metabolismThe American Journal of Clinical Nutrition, Vol. 86, No. 2Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction16 November 2005 | Nutrition & Metabolism, Vol. 2, No. 1 Volume 3Issue 1Mar 2005 InformationCopyright 2005, Mary Ann Liebert, Inc.To cite this article:Eric C. Westman, William S. YancyJr., Mark D. Haub, and Jeff S. Volek.Insulin Resistance from a Low Carbohydrate, High Fat Diet Perspective.Metabolic Syndrome and Related Disorders.Mar 2005.14-18.http://doi.org/10.1089/met.2005.3.14Published in Volume: 3 Issue 1: July 5, 2005PDF download

Colgate-Palmolive Co.

Mergent's Dividend AchieversVolume 2, Issue 2 p. 62-62 U.S. Company Report Colgate-Palmolive Co.† First published: 22 April 2005 https://doi.org/10.1002/div.2233 † Contact: : Reuben Mark — Chmn., C.E.O. Address: : 300 Park Avenue, New York, NY 10022-7499 Web Site: : www.colgate.com AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Chemicals (MIC: 11.1 SIC: 844 NAIC: 25620) Colgate-Palmolive is a consumer products company whose products are marketed in over 200 countries worldwide. Co. operates in two business segments. Co.'s oral, personal, household surface and fabric care segment include toothpaste, oral rinses and toothbrushes, hand soaps, shower gels, shampoos, deodorants, shave products, laundry and dishwashing detergents, cleansers and other similar items. Co.'s pet nutrition segment includes pet food products manufactured and marketed by Hill's Pet Nutrition. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to other regional trademarks. Volume2, Issue2Spring 2005Pages 62-62 RelatedInformation

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC:325620)Colgate‐Palmolive is a consumer products company whose products are marketed in over 200 countries worldwide. Co. operates in two business segments. Co.'s oral, personal, household surface and fabric care segment include toothpaste, oral rinses and toothbrushes, hand soaps, shower gels, shampoos, deodorants, shave products, laundry and dishwashing detergents, cleansers and other similar items. Co.'s pet nutrition segment includes pet food products manufactured and marketed by Hill's Pet Nutrition. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to other regional trademarks.

Colgate‐Palmolive Co.

AbstractChemicals (MIC: 11.1 SIC: 2844 NAIC:325620)Colgate‐Palmolive is a consumer products company whose products are marketed in over 200 countries worldwide. Co. operates in two business segments. Co.'s oral, personal, household surface and fabric care segment include toothpaste, oral rinses and toothbrushes, hand soaps, shower gels, shampoos, deodorants, shave products, laundry and dishwashing detergents, cleansers and other similar items. Co.'s pet nutrition segment includes pet food products manufactured and marketed by Hill's Pet Nutrition. Principal global trademarks include Colgate, Palmolive, Kolynos, Sorriso, Mennen, Protex, Ajax, Soupline, Suavitel, Fab, Science Diet and Prescription Diet in addition to other regional trademarks.

Errata

Journal of Human Nutrition and DieteticsVolume 16, Issue 3 p. 215-215 Free Access Errata First published: 10 September 2009 https://doi.org/10.1046/j.0952-3871.2002.00353.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat F. C. Taylor, L. J. Irons, P. Finn and C. D. Summerbell Controlled clinical trial of two weight reducing diets in a NHS hospital dietetic outpatient clinc – a pilot study. Journal of Human Nutrition and Dietetics 2003, 16, 85–87. 1. The correspondence details on page 85 should read: Fiona TaylorSenior Community Dietitian,Dietetic Department,Guisborough General Hospital,Guisborough TS14 6HZ, UK.Tel.: 01287 284000Fax.: 01287 284085 E-mail: fiona.taylor@tney.northy.nhs.uk 2. The last sentence of the conclusions section in the abstract on page 85 should read: Mean weight loss was greater by about 50% in the healthy eating group and supports the development of a larger trial to estimate true effect. 3. The second sentence of the Materials and Methods section on page 85 should read: Eligible patients were alternatively allocated to one of the two dietary programmes and asked to attend four (every 4 weeks) individual consultations with the dietitian. 4. The first sentence of the fourth paragraph of column one on page 86 should read: At the first appointment the dietitian explained the dietary programme. 5. The first sentence of the fourth paragraph of column one on page 86 should read: Completers were defined as patients who attended their first and final 12-week appointment. 6. The first sentence of the Discussion section on page 87 should read: The additional mean weight loss (2 kg) achieved by patients on the healthy eating diet, compared with the energy prescription diet, who completed this 12-week trial was clinically important, although this difference was not statistically significant. 7. The final part of the first paragraph of the Discussion section on page 87 should read: Some 27 of the of the 53 (51%) patients who attended their first appointment completed the study. The attrition rate (49%) suggests that these dietary programmes were of little value to many patients who were referred to the dietetic department. The “did not attend” rate in this study, although high is similar to those reported by others (MacQueen et al., 1995). It is of interest that 26% of patients who did not attend their first appointment were from one of the most socially disadvantaged areas of Teesside. 8. The following reference was omitted from the list on page 87: References MacQueen, C. & Frost, G. (1995) Does high quality information improve the attendance rate or treatment outcome of obese patients? J. Hum. Diet. 8, 137– 139. Blackwell Publishing apologise unreservedly to the authors of the article as well as Gary Frost and Lorna Hall for the errors that have occurred and the inconvenience caused. Volume16, Issue3June 2003Pages 215-215 ReferencesRelatedInformation

日本の犬ぞり犬における運動処方作成上の問題点と高タンパク, 高脂肪の特別療法食追加給餌の影響

Various investigations for prescribing exercise regimens for sled dogs in Japan suggested the animals should be divided into groups according to things like age: older or younger than five. It was also suggested that factors like lactate threshold and acid-base balance are useful for setting individual-dog per-session exercise loads and that a second session might prevent over-exercising. PRESCRIPTION DIET® a/d (a/d) high-fat, high-protein supplements were added to ordinary feed in some cases.In the supplement group compared with animals not fed the supplement, no significant Post-exercise rise in AST was obcerved, and HCO3 and PCO2 recovery was fast. Some anxiety was felt, however, about giving excessive electrolytes because of a rise in plasma osmotic pressure associated with a rise in sodium and chloride after a/d supply unrelated to exercise load. In addition, the need for an ample supply of water was indicated.